RBC Capital analyst Luca Issi raised the firm’s price target on Crispr Therapeutics to $66 from $57 and keeps a Sector Perform rating on the shares after its “incremental” Q4 earnings update. With the “historic” approval of Casgevy in the U.S., E.U., Great Britain, Bahrain, and Saudi Arabia, the focus for the company remains on launch execution, the analyst tells investors in a research note. Phase I studies are ongoing for ANG3 and Lp(a), but while the firm “appreciates” all the progress, it also remains cautious on the launch and “struggles” to see upside following the recent move, RBC added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Crispr Therapeutics reports Q4 EPS $1.10, consensus (7c)
- Crispr Therapeutics options imply 7.2% move in share price post-earnings
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- Crispr Therapeutics initiated with a Peer Perform at Wolfe Research